Cervical Dystonia: Disease-Characteristics Research Report

Scope and evidence note

This report prioritizes 2023–2024 literature retrieved for this review. Cervical-dystonia (CD)-specific human evidence is distinguished from evidence about dystonia generally. Some requested database fields—particularly exact MONDO/Orphanet/HPO accessions, population allele frequencies, and active ClinicalTrials.gov records—could not be independently queried in the available retrieval environment; such fields are marked for ontology-database verification rather than inferred.

Table: This table condenses key cervical dystonia knowledge-base facts across clinical, genetic, mechanistic, diagnostic, therapeutic, prognostic, and model domains. It distinguishes cervical-dystonia-specific evidence from broader dystonia findings and attaches ontology suggestions plus source metadata for downstream curation.

1. Disease information

Definition. Cervical dystonia is a focal dystonia in which sustained or intermittent involuntary contractions of cervical muscles produce patterned, often twisting or repetitive head/neck movements and abnormal postures. It was historically called spasmodic torticollis. Presentations include torticollis, laterocollis/laterocaput, antecollis/antecaput, retrocollis/retrocaput, sagittal or lateral shift, and combinations thereof. Dystonic head tremor, muscle hypertrophy, pain, overflow activation, and a relieving maneuver (“geste antagoniste” or sensory trick, such as touching the chin) support the diagnosis. The current expert framework classifies dystonia on two axes: clinical characteristics—age at onset, distribution, temporal pattern, and associated features—and etiology. “Focal” means one body region; isolated dystonia permits tremor but no other movement disorder. (thomsen2024geneticsandpathogenesis pages 2-4, thomsen2024geneticsandpathogenesis pages 1-2)

Suggested identifiers. ICD-10-CM G24.3 (“spasmodic torticollis”); ICD-11 is within the dystonia/movement-disorder hierarchy; MeSH concepts include Dystonic Disorders and Torticollis. Common synonyms are cervical dystonia, spasmodic torticollis, adult-onset idiopathic cervical dystonia, idiopathic rotational torticollis, and focal neck dystonia. The exact current MONDO and Orphanet accessions should be resolved against the live ontology release before database ingestion; cervical dystonia should not be conflated with generalized “isolated dystonia” or congenital muscular torticollis.

The evidence summarized here is primarily aggregated disease-level evidence from registries, cohorts, reviews, and experimental models—not individual EHR-derived patient data. One important recent source analyzed 1,701 patients from 42 Italian movement-disorder centers using a common specialist protocol. (velucci2024doessexinfluence pages 1-2)

Exact abstract wording from a 2024 authoritative review: “Dystonia is a clinically and genetically highly heterogeneous neurological disorder characterized by abnormal movements and postures caused by involuntary sustained or intermittent muscle contractions.” DOI: https://doi.org/10.1146/annurev-pathmechdis-051122-110756; first online September 22, 2023; issue date January 2024. (thomsen2024geneticsandpathogenesis pages 1-2)

2. Etiology, risk, protective factors, and gene–environment interaction

Most typical adult-onset isolated CD is idiopathic and multifactorial, not a single-gene disorder. Current models invoke a susceptible motor network in which polygenic/developmental factors interact with age-, sex-, and possibly exposure-dependent triggers. Acquired cervical dystonia can follow structural brain injury, neuroleptic or dopamine-blocking drugs, neurodegenerative disease, infection/autoimmunity, or peripheral trauma, but causality for many reported environmental associations remains uncertain. A subacute, rapidly progressive, relapsing, or neurologically complex presentation should prompt investigation for acquired/autoimmune disease rather than classification as idiopathic CD. (bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2, thomsen2024geneticsandpathogenesis pages 2-4)

Risk factors supported most consistently: middle or later adult age, female sex, and family history of dystonia or tremor. In the Italian registry, CD had a female:male ratio of 1.9 (95% CI 1.8–2.1) at last examination and 1.9 (1.7–2.0) at onset. Family history of dystonia or tremor occurred in 11.1% across idiopathic adult-onset dystonia, although this was not CD-specific. The authors proposed that age-related sexual dimorphism could reflect interactions between environmental exposures and hormonal/biological factors; this is a hypothesis rather than a proven causal mechanism. (velucci2024doessexinfluence pages 1-2, velucci2024doessexinfluence pages 2-3)

No replicated protective genetic variant, diet, exercise pattern, medication, or exposure has been shown to prevent idiopathic CD. Alcohol may transiently reduce some dystonic symptoms but is not protective and carries dependence risk. Smoking, diet, exercise, and occupational exposures do not currently support actionable prevention recommendations. No infectious agent is established as the cause of ordinary idiopathic CD.

3. Phenotypes and quality-of-life effects

The principal phenotype is persistent or action-aggravated abnormal head posture with patterned cervical muscle activation. Severity ranges from mild intermittent pulling to fixed, painful postures causing substantial disability. CD usually begins at 45–50 years and generally remains focal, although craniocervical or other segmental spread can occur. (salamon2023geneticscreeningof pages 1-2)

Suggested phenotype annotations include:

• Torticollis/abnormal head posture—clinical sign; HPO HP:0002418 (Torticollis) and abnormal head-posture terms.
• Dystonia—motor sign; HP:0001332.
• Dystonic head tremor—sign; HP:0001336 (Tremor), with a dystonic-tremor qualifier.
• Neck pain—symptom; HP:0012531 (Pain) plus neck localization. In the 2024 registry, neck pain affected 488/848 CD cases (57.5%); older systematic-review estimates were 67–75%, illustrating cohort and ascertainment differences. (velucci2024doessexinfluence pages 2-3, kuyper2011nonmotormanifestationsof pages 4-5)
• Sensory trick/geste antagoniste—supportive sign; 28.4% across the complete adult-onset dystonia registry, not solely CD. (velucci2024doessexinfluence pages 2-3)
• Restricted cervical range of motion, muscle spasm/hypertrophy, dysphagia or dysphonia where relevant—use the corresponding HPO terms after phenotype-level confirmation.
• Anxiety, depression, embarrassment, social avoidance, sleep disturbance, and fatigue—nonmotor manifestations requiring separate assessment. An older study summarized in a systematic review found 71% lifetime social phobia among 116 people with spasmodic torticollis, associated more with body image and maladaptive illness attitudes than objective motor severity. (kuyper2011nonmotormanifestationsof pages 4-5)

Pain, visible postural abnormality, tremor, and unpredictable symptom fluctuation interfere with driving, reading, work, sleep, social interaction, and activities of daily living. Motor severity alone therefore incompletely represents quality of life; CD-specific instruments such as the Cervical Dystonia Impact Profile and Toronto Western Spasmodic Torticollis Rating Scale should be complemented by pain, mood, sleep, and participation measures.

4. Genetic and molecular information

CD is genetically heterogeneous. Confirmed monogenic dystonias that can include prominent cervical or craniocervical involvement include THAP1, GNAL, ANO3, TOR1A, and in selected complex or early-onset cases KMT2B, VPS16, SGCE, ADCY5, ATP1A3, GCH1, EIF2AK2, PRKRA, among others. The 2024 review listed 52 well-supported monogenic dystonia genes in the 2022 MDS nomenclature update, while more than 400 genes had been associated with dystonia or dystonic symptoms at varying evidence levels. This broader number must not be interpreted as 400 established CD genes. (thomsen2024geneticsandpathogenesis pages 2-4, thomsen2024geneticsandpathogenesis pages 1-2)

In a 2023 Hungarian study of 121 unrelated focal-dystonia patients—74 CD and 47 blepharospasm—a 30-gene panel identified 209 heterozygous variants in 24 genes. Nine variants were judged clinically/genetically relevant, yielding 7.4%, although six were VUS and no functional testing was performed. Relevant variants occurred almost exclusively in CD and disproportionately in earlier-onset cases (mean onset 31.6 years). (salamon2023geneticscreeningof pages 1-2, salamon2023geneticscreeningof pages 5-6)

Reported CD-associated candidates included ANO3 c.2276-6T>C, CIZ1 c.1820A>G (p.Glu607Gly), KCNN2 c.1625G>A (p.Arg542Gln), KMT2B c.3136C>T (p.Arg1046Cys), and VPS16 c.1370T>C (p.Leu457Pro). These were chiefly VUS and should not be entered as established pathogenic variants without updated ClinVar/ClinGen review, segregation, population-frequency evaluation, and functional evidence. (salamon2023geneticscreeningof pages 5-6)

The best-characterized inherited forms are generally germline, with autosomal-dominant inheritance and incomplete penetrance common among isolated dystonias. Variable expressivity is substantial. Somatic mosaicism, anticipation, and recurrent chromosomal abnormalities are not recognized defining features of ordinary CD. No robust CD-specific modifier gene or clinically validated epigenetic signature is established. Population allele frequencies must be obtained variant-by-variant from the current gnomAD release; rare-disease pathogenic variants are generally expected to be absent or extremely rare, but no frequency should be assigned from disease reports alone.

5. Environmental and lifestyle information

The evidence for environmental causation in idiopathic CD is weaker than the evidence for age, sex, and genetic susceptibility. Clinicians should document dopamine-receptor-blocking drug exposure, neck/peripheral trauma, structural CNS injury, occupational repetitive activity, toxins, and infections, but distinguish temporal association from causality. Acute or subacute focal dystonia is atypical for ordinary idiopathic CD and raises concern for drug-induced, structural, metabolic, or autoimmune disease. There is no validated diet, exercise regimen, smoking pattern, alcohol exposure, pollution exposure, radiation source, or pathogen that specifically causes or prevents typical CD.

6. Mechanism and pathophysiology

The prevailing view is a distributed network disorder, not a primary cervical-muscle disease and not solely a basal-ganglia disorder. The implicated network comprises cerebral sensorimotor cortex, striatum and pallidum, thalamus, cerebellum, and brainstem. Core physiological abnormalities are impaired sensorimotor integration, deficient inhibition at cortical, basal-ganglia, brainstem, and spinal levels, maladaptive plasticity, and faulty motor “gating.” The causal chain proposed for idiopathic CD is: inherited/developmental susceptibility plus incompletely defined environmental or physiological triggers → altered synaptic signaling and plasticity in basal-ganglia–cerebellar–thalamo–cortical circuits → reduced surround inhibition and poor suppression of competing motor programs → simultaneous agonist/antagonist and overflow muscle activation → patterned head posture, tremor, and pain. (bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2, thomsen2024geneticsandpathogenesis pages 1-2)

Molecular groupings include neurodevelopmental transcription (KMT2B, THAP1), calcium homeostasis (ANO3, HPCA), striatal dopamine/cAMP signaling (GNAL), endoplasmic-reticulum stress (TOR1A, EIF2AK2, PRKRA), and autophagy/lysosomal trafficking (VPS16). These pathways derive mainly from genetic dystonia rather than common idiopathic CD, but may expose convergent therapeutic mechanisms. (thomsen2024geneticsandpathogenesis pages 1-2)

Rodent work supports abnormal dopamine–acetylcholine balance, glutamatergic transmission, receptor trafficking, and corticostriatal plasticity. In DYT-TOR1A models, D2-receptor activation can paradoxically excite striatal cholinergic interneurons, increasing acetylcholine and impairing corticostriatal long-term depression/depotentiation. Cerebellar Purkinje-cell and deep-nuclear firing abnormalities also correlate with dystonic movements. (wilson2013animalmodelsfor pages 4-5, atiallah2023synapticdysfunctionin pages 4-5, atiallah2023synapticdysfunctionin pages 1-2)

Suggested annotations are GO: synaptic signaling; regulation of synaptic plasticity; long-term synaptic depression; dopamine-receptor signaling; cholinergic synaptic transmission; calcium-ion homeostasis; response to ER stress; autophagy. Suggested cell types are striatal medium spiny/projection neuron, striatal cholinergic interneuron, cerebellar Purkinje cell, deep cerebellar nuclear neuron, thalamic neuron, and cortical pyramidal neuron. There is no validated CD-specific immune, metabolomic, lipidomic, methylomic, proteomic, single-cell, spatial-transcriptomic, or multi-omic diagnostic signature. Available advanced-omics evidence is mostly from monogenic models and remains investigational.

7. Anatomical structures affected

At the effector level, CD affects skeletal muscles of the neck and upper shoulder girdle, commonly including sternocleidomastoid, splenius capitis/cervicis, semispinalis, levator scapulae, trapezius, scalene, and deep suboccipital muscles. Activation is usually asymmetric but can be bilateral. Secondary effects include cervical pain, restricted mobility, degenerative musculoskeletal strain, and occasionally dysphagia.

At the nervous-system level, implicated sites are motor/premotor and somatosensory cortex, striatum, globus pallidus, thalamus, cerebellar cortex/deep nuclei, and brainstem. Suggested UBERON annotations are neck region, skeletal muscle of neck, cerebral cortex, basal ganglion, globus pallidus, thalamus, cerebellum, brainstem. Relevant subcellular compartments in genetic forms include ER/nuclear envelope (torsinA), synapse/presynaptic vesicle machinery, plasma-membrane signaling complexes, and lysosome/autophagosome. (atiallah2023synapticdysfunctionin pages 4-5, bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2)

8. Temporal development

Typical onset is insidious in middle adulthood, often initially intermittent and aggravated by action, stress, fatigue, or particular head positions. Symptoms commonly evolve over months to several years before becoming relatively stable, although day-to-day fluctuation persists. CD is generally chronic and lifelong. Spread is less common than in blepharospasm but may produce craniocervical or other segmental dystonia. Spontaneous remissions are reported clinically but are uncommon and may relapse; no evidence supports a predictable critical window for disease prevention. Early specialist diagnosis is nevertheless valuable because prolonged diagnostic delay extends pain, disability, and ineffective care. (salamon2023geneticscreeningof pages 1-2, zhao2024longtermfollowupof pages 1-2)

9. Inheritance and population epidemiology

Dystonia was historically classified as rare, but recent estimates cited in the 2024 review placed isolated dystonia overall at 30.9–52.7 per 100,000; true prevalence may be higher because of underdiagnosis and misdiagnosis. These are not CD-specific prevalence estimates. (thomsen2024geneticsandpathogenesis pages 2-4)

In the Italian registry, 848/1,701 patients had cervical involvement at final examination; 558 were women and 290 men. Neck pain prevalence did not differ materially by sex. The study also supports female predominance in craniocervical dystonia, while task-specific upper-limb dystonia showed male predominance. (velucci2024doessexinfluence pages 2-3)

Geographic estimates vary with ascertainment and ancestry. A 2024 craniocervical-dystonia report cited a roughly threefold higher CD incidence among White than Asian populations, but this secondary statement requires confirmation in the original multiethnic epidemiologic study before population-risk annotation. (zhao2024longtermfollowupof pages 1-2)

Most CD is sporadic/multifactorial. Monogenic cases can be autosomal dominant with reduced penetrance and variable expressivity; recessive and other inheritance patterns occur in broader dystonia syndromes. Founder effects, carrier frequency, anticipation, germline mosaicism, and consanguinity are gene- and variant-specific rather than general CD properties.

10. Diagnosis

Diagnosis is clinical and should be made by a clinician experienced in movement disorders. Examination establishes the posture/movement pattern, active muscles, tremor, pain, sensory tricks, task dependence, range of motion, and spread. Standardized scales include TWSTRS, Tsui score, Cervical Dystonia Impact Profile, and pain/quality-of-life measures. Surface or needle EMG and ultrasound help identify injection targets but are not standalone diagnostic biomarkers.

MRI or CT is appropriate when onset or examination suggests a structural cause. In the Italian registry, all patients underwent brain MRI or CT, with Wilson-disease testing and testing of TOR1A, THAP1, ANO3, and GNAL when appropriate. (velucci2024doessexinfluence pages 1-2)

There is no diagnostic blood, CSF, tissue, electrophysiologic, imaging, proteomic, metabolomic, or liquid-biopsy biomarker for idiopathic CD. Genetic testing is highest yield with onset before approximately 20–30 years, positive family history, generalized/segmental spread, developmental or additional neurologic features, or an atypical course. A dystonia panel is a reasonable first test; WES/WGS is appropriate when panel testing is unrevealing and suspicion remains high. CMA, karyotype, FISH, mitochondrial testing, and repeat-expansion testing are not routine for typical adult-onset isolated CD but may be indicated by syndromic features. The 2023 focal-dystonia cohort found no clear WES-yield advantage over a curated panel in its small WES subset. (salamon2023geneticscreeningof pages 5-6)

Differential diagnoses include essential or dystonic tremor, Parkinsonian anterocollis, tics, functional dystonia, congenital/orthopedic torticollis, cervical radiculopathy, atlantoaxial disease, drug-induced/tardive dystonia, Wilson disease, structural lesions, neurodegenerative or metabolic dystonia, autoimmune encephalitis, and craniocervical dystonia/Meige syndrome. Population or newborn screening is not recommended. Cascade testing is appropriate only after a clearly pathogenic familial variant is established.

11. Outcome and prognosis

CD generally does not shorten life expectancy, and disease-specific survival statistics are not clinically applicable. Its burden is morbidity: pain, impaired head control, tremor, sleep disturbance, reduced employment and driving, anxiety/depression, social isolation, and treatment burden. Fixed postures, orthopedic strain, dysphagia, and treatment-related neck weakness are possible complications.

Prognosis is heterogeneous. Many patients obtain meaningful symptomatic control with individualized botulinum-neurotoxin treatment, but treatment must be repeated. Motor response does not guarantee resolution of pain, mood, sleep, or social disability. No validated molecular prognostic biomarker predicts spread, remission, toxin response, or DBS response.

12. Treatment and recent developments

Botulinum neurotoxin

Intramuscular botulinum neurotoxin is the standard first-line treatment. BoNT/A products include onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and the longer-acting daxibotulinumtoxinA-lanm; rimabotulinumtoxinB is a BoNT/B option. Products are not dose-unit interchangeable. The toxin cleaves SNARE proteins in cholinergic terminals, reducing acetylcholine release and excessive muscle contraction. Muscle selection should follow the observed posture and collum–caput pattern, with ultrasound and/or EMG guidance for deep or difficult targets. (salamon2023geneticscreeningof pages 1-2)

Common adverse effects are dysphagia, neck weakness, local pain, dry mouth, flu-like symptoms, and excessive weakness. Apparent nonresponse should prompt reassessment of diagnosis, muscle selection, dose, guidance, injection interval, fixed contracture, and rarely neutralizing antibodies.

A 2024 review documented continued formulation development, including prabotulinumtoxinA/ABP-450 (phase 2), neubotulinumtoxinA (phase 3), and A2NTX (phase 1) for CD at the time reviewed. These pipeline statuses require confirmation against the current trial registry. DOI: https://doi.org/10.3390/toxins16060261; published June 2024. (rasettiescargueil2024embracingtheversatility pages 9-10)

Suggested NCIt concepts: Botulinum Toxin Type A, Botulinum Toxin Type B, intramuscular injection, electromyography-guided injection, ultrasonography-guided injection.

Oral, supportive, and rehabilitative treatment

Oral drugs are generally adjunctive and have weaker evidence than BoNT: trihexyphenidyl, clonazepam or other benzodiazepines, baclofen, and selected dopamine-modulating agents. Treatment should address pain, depression/anxiety, sleep, and occupational limitations. Physical therapy emphasizing sensorimotor retraining, posture, active exercise, and home programs may complement BoNT; forceful passive manipulation should be avoided. Occupational, psychological, and pain-management support are often appropriate.

Deep-brain stimulation and surgery

Bilateral globus pallidus internus DBS is an option for severe medically refractory CD/segmental craniocervical dystonia. In a 2024 retrospective series of 24 refractory craniocervical-dystonia patients, mean BFMDRS motor score improved 55.3% at six months and 56.6% at a mean 37.5-month follow-up; six patients (25%) had less than 30% improvement, demonstrating important response variability. DOI: https://doi.org/10.3171/2024.3.FOCUS23890; published June 2024. (zhao2024longtermfollowupof pages 5-6, zhao2024longtermfollowupof pages 1-2)

Selective peripheral denervation is now less common but may be considered at specialized centers. Gene, cell, RNA, and immune therapies are not established for idiopathic CD. Genotype-directed treatment applies mainly to a minority of broader dystonia syndromes—for example levodopa-responsive GCH1 disease—not to routine adult-onset CD.

13. Prevention

There is no proven primary prevention, vaccine, prophylactic drug, population screening program, or validated behavioral intervention for idiopathic CD. Avoiding unnecessary dopamine-receptor-blocking drugs may reduce tardive dystonia risk but does not prevent idiopathic CD. Secondary prevention consists of prompt recognition of patterned dystonia and investigation of atypical or treatable acquired causes. Tertiary prevention includes optimized BoNT treatment, rehabilitation, pain and psychiatric care, swallowing monitoring, avoidance of fixed contractures, and DBS evaluation where appropriate. Genetic counseling is indicated for pathogenic variants or strong familial disease; prenatal or preimplantation testing is relevant only after a well-established familial pathogenic variant and individualized counseling.

14. Other species and naturally occurring disease

No well-established naturally occurring veterinary disorder is a direct homolog of common adult-onset idiopathic human CD. Animals may display torticollis from vestibular, infectious, toxic, traumatic, or structural disease, but this is not equivalent to human cervical dystonia. There is no zoonotic transmission. Orthologous dystonia genes are highly conserved across mammals, enabling mechanistic models, but veterinary breed-specific and VBO annotations should not be assigned without OMIA/VetCompass confirmation.

15. Model organisms

Models include genetic knock-in/knockout/conditional mice for Tor1a, Thap1, Gnal, Sgce, pharmacologic and lesion models in mice/rats, and toxin or pallidal-manipulation models in nonhuman primates. Dystonic rats carrying Caytaxin defects and tottering mice with Cacna1a/Cav2.1 dysfunction exhibit abnormal Purkinje/deep-cerebellar-nuclear firing correlated with dystonic movements. Cerebellar lesion or inactivation can suppress dystonia in several models, while targeted glutamatergic stimulation can provoke it. (wilson2013animalmodelsfor pages 4-5)

Modern optogenetic and chemogenetic studies permit cell- and circuit-specific perturbation of basal-ganglia and cerebellar pathways. A 2024 review concluded that both systems are pathologically altered but emphasized that exact causal cell populations remain unresolved. DOI: https://doi.org/10.3389/dyst.2024.11793; published February 19, 2024. (rauschenberger2024unravelingdystoniacircuitry pages 1-2)

These models have construct validity for particular monogenic dystonias and are useful for synaptic physiology, developmental timing, circuit mapping, DBS mechanisms, and target discovery. Their principal limitation is that many do not reproduce spontaneous adult-onset focal neck dystonia; some show only subtle physiology or generalized dystonia-like movements. Findings therefore support convergent dystonia mechanisms but cannot automatically be treated as CD-specific human biology.

Overall expert interpretation

Cervical dystonia is best represented in a knowledge base as a complex, predominantly sporadic adult-onset focal network disorder with occasional monogenic causes. Its defining data layer should prioritize clinical phenomenology, neck pain, tremor, sensory tricks, disability, and treatment response. Genetic entries should carry evidence-level qualifiers: THAP1, GNAL, and ANO3 are credible causes of inherited dystonia with cervical involvement, whereas many recently observed focal-dystonia variants remain VUS. The most mature real-world intervention is individualized, repeatedly administered botulinum neurotoxin; GPi-DBS is effective for selected refractory disease but has meaningful nonresponse and durability uncertainty. The largest gaps are validated biomarkers, CD-specific multi-omics, firmly replicated gene–environment interactions, preventive strategies, and models that faithfully reproduce adult-onset focal cervical disease. (thomsen2024geneticsandpathogenesis pages 1-2, salamon2023geneticscreeningof pages 5-6, zhao2024longtermfollowupof pages 1-2)

References

1. (thomsen2024geneticsandpathogenesis pages 1-2): Mirja Thomsen, Lara M. Lange, Michael Zech, and Katja Lohmann. Genetics and pathogenesis of dystonia. Annual Review of Pathology: Mechanisms of Disease, 19:99-131, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-110756, doi:10.1146/annurev-pathmechdis-051122-110756. This article has 117 citations and is from a domain leading peer-reviewed journal.

2. (thomsen2024geneticsandpathogenesis pages 2-4): Mirja Thomsen, Lara M. Lange, Michael Zech, and Katja Lohmann. Genetics and pathogenesis of dystonia. Annual Review of Pathology: Mechanisms of Disease, 19:99-131, Jan 2024. URL: https://doi.org/10.1146/annurev-pathmechdis-051122-110756, doi:10.1146/annurev-pathmechdis-051122-110756. This article has 117 citations and is from a domain leading peer-reviewed journal.

3. (velucci2024doessexinfluence pages 1-2): Vittorio Velucci, Sarah Idrissi, R. Pellicciari, Marcello Esposito, Assunta Trinchillo, D. Belvisi, Giovanni Fabbrini, G. Ferrazzano, C. Terranova, P. Girlanda, Giovanni Majorana, V. Rizzo, Francesco Bono, Giovanni Idone, Vincenzo Laterza, L. Avanzino, F. di Biasio, R. Marchese, A. Castagna, M. Ramella, C. Lettieri, S. Rinaldo, M. C. Altavista, Luigi Polidori, L. Bertolasi, M. C. Tozzi, R. Erro, P. Barone, Pierangelo Barbero, R. Ceravolo, M. Mascia, Tommaso Ercoli, A. Muroni, C. Artusi, M. Zibetti, C. Scaglione, A. Bentivoglio, Maria Sofia Cotelli, L. Magistrelli, G. Cossu, A. Albanese, G. Squintani, T. Schirinzi, A. Gigante, L. Maderna, R. Eleopra, Antonio Pisani, D. Cassano, M. Romano, Marina Rizzo, A. Berardelli, and G. Defazio. Does sex influence the natural history of idiopathic adult-onset dystonia? Journal of Neurology, Neurosurgery, and Psychiatry, 95:784-790, Mar 2024. URL: https://doi.org/10.1136/jnnp-2023-332927, doi:10.1136/jnnp-2023-332927. This article has 12 citations.

4. (velucci2024doessexinfluence pages 2-3): Vittorio Velucci, Sarah Idrissi, R. Pellicciari, Marcello Esposito, Assunta Trinchillo, D. Belvisi, Giovanni Fabbrini, G. Ferrazzano, C. Terranova, P. Girlanda, Giovanni Majorana, V. Rizzo, Francesco Bono, Giovanni Idone, Vincenzo Laterza, L. Avanzino, F. di Biasio, R. Marchese, A. Castagna, M. Ramella, C. Lettieri, S. Rinaldo, M. C. Altavista, Luigi Polidori, L. Bertolasi, M. C. Tozzi, R. Erro, P. Barone, Pierangelo Barbero, R. Ceravolo, M. Mascia, Tommaso Ercoli, A. Muroni, C. Artusi, M. Zibetti, C. Scaglione, A. Bentivoglio, Maria Sofia Cotelli, L. Magistrelli, G. Cossu, A. Albanese, G. Squintani, T. Schirinzi, A. Gigante, L. Maderna, R. Eleopra, Antonio Pisani, D. Cassano, M. Romano, Marina Rizzo, A. Berardelli, and G. Defazio. Does sex influence the natural history of idiopathic adult-onset dystonia? Journal of Neurology, Neurosurgery, and Psychiatry, 95:784-790, Mar 2024. URL: https://doi.org/10.1136/jnnp-2023-332927, doi:10.1136/jnnp-2023-332927. This article has 12 citations.

5. (salamon2023geneticscreeningof pages 1-2): András Salamon, Zsófia Flóra Nagy, Margit Pál, Máté Szabó, Ádám Csősz, László Szpisjak, Gabriella Gárdián, Dénes Zádori, Márta Széll, and Péter Klivényi. Genetic screening of a hungarian cohort with focal dystonia identified several novel putative pathogenic gene variants. International Journal of Molecular Sciences, 24:10745, Jun 2023. URL: https://doi.org/10.3390/ijms241310745, doi:10.3390/ijms241310745. This article has 8 citations.

6. (kuyper2011nonmotormanifestationsof pages 4-5): Daniel J. Kuyper, Veronica Parra, Shanae Aerts, Michael S. Okun, and Benzi M. Kluger. Nonmotor manifestations of dystonia: a systematic review. Movement Disorders, 26:1206-1217, Jun 2011. URL: https://doi.org/10.1002/mds.23709, doi:10.1002/mds.23709. This article has 264 citations and is from a highest quality peer-reviewed journal.

7. (bruggemann2021contemporaryfunctionalneuroanatomy pages 1-2): Norbert Brüggemann. Contemporary functional neuroanatomy and pathophysiology of dystonia. Journal of Neural Transmission, 128:499-508, Jan 2021. URL: https://doi.org/10.1007/s00702-021-02299-y, doi:10.1007/s00702-021-02299-y. This article has 77 citations and is from a peer-reviewed journal.

8. (salamon2023geneticscreeningof pages 5-6): András Salamon, Zsófia Flóra Nagy, Margit Pál, Máté Szabó, Ádám Csősz, László Szpisjak, Gabriella Gárdián, Dénes Zádori, Márta Széll, and Péter Klivényi. Genetic screening of a hungarian cohort with focal dystonia identified several novel putative pathogenic gene variants. International Journal of Molecular Sciences, 24:10745, Jun 2023. URL: https://doi.org/10.3390/ijms241310745, doi:10.3390/ijms241310745. This article has 8 citations.

9. (rauschenberger2024unravelingdystoniacircuitry pages 1-2): Lisa Rauschenberger and Chi Wang Ip. Unraveling dystonia circuitry in rodent models using novel neuromodulation techniques. Dystonia, Feb 2024. URL: https://doi.org/10.3389/dyst.2024.11793, doi:10.3389/dyst.2024.11793. This article has 2 citations.

10. (atiallah2023synapticdysfunctionin pages 1-2): Ilham El Atiallah, Paola Bonsi, Annalisa Tassone, Giuseppina Martella, Gerardo Biella, Antonio N. Castagno, Antonio Pisani, and Giulia Ponterio. Synaptic dysfunction in dystonia: update from experimental models. Current Neuropharmacology, 21:2310-2322, Nov 2023. URL: https://doi.org/10.2174/1570159x21666230718100156, doi:10.2174/1570159x21666230718100156. This article has 11 citations and is from a peer-reviewed journal.

11. (atiallah2023synapticdysfunctionin pages 4-5): Ilham El Atiallah, Paola Bonsi, Annalisa Tassone, Giuseppina Martella, Gerardo Biella, Antonio N. Castagno, Antonio Pisani, and Giulia Ponterio. Synaptic dysfunction in dystonia: update from experimental models. Current Neuropharmacology, 21:2310-2322, Nov 2023. URL: https://doi.org/10.2174/1570159x21666230718100156, doi:10.2174/1570159x21666230718100156. This article has 11 citations and is from a peer-reviewed journal.

12. (rasettiescargueil2024embracingtheversatility pages 9-10): Christine Rasetti-Escargueil and Stefano Palea. Embracing the versatility of botulinum neurotoxins in conventional and new therapeutic applications. Toxins, 16:261, Jun 2024. URL: https://doi.org/10.3390/toxins16060261, doi:10.3390/toxins16060261. This article has 37 citations.

13. (zhao2024longtermfollowupof pages 1-2): Zhuoling Zhao, Zhiwei Ren, Yongsheng Hu, Kaijia Yu, Fangzhao Yin, Jianyu Li, and Guojun Zhang. Long-term follow-up of pallidal deep brain stimulation for craniocervical dystonia: is the globus pallidus internus the best target? Neurosurgical focus, 56 6:E16, Jun 2024. URL: https://doi.org/10.3171/2024.3.focus23890, doi:10.3171/2024.3.focus23890. This article has 2 citations.

14. (zhao2024longtermfollowupof pages 5-6): Zhuoling Zhao, Zhiwei Ren, Yongsheng Hu, Kaijia Yu, Fangzhao Yin, Jianyu Li, and Guojun Zhang. Long-term follow-up of pallidal deep brain stimulation for craniocervical dystonia: is the globus pallidus internus the best target? Neurosurgical focus, 56 6:E16, Jun 2024. URL: https://doi.org/10.3171/2024.3.focus23890, doi:10.3171/2024.3.focus23890. This article has 2 citations.

15. (wilson2013animalmodelsfor pages 4-5): Bethany K. Wilson and Ellen J. Hess. Animal models for dystonia. Movement Disorders, 28:982-989, Jun 2013. URL: https://doi.org/10.1002/mds.25526, doi:10.1002/mds.25526. This article has 84 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.